This agreement will allow the diagnostic information services company to expand its operations in Ohio.
Quest Diagnostics agreed to acquire select assets of University Hospital’s outreach laboratory services business.1 This will increase Quest’s presence in Ohio and allow it to provide its services to a broader network within the state.
In a press release, University Hospitals CEO Cliff A. Megerian said, “Laboratory testing is a critical and increasingly complex area of healthcare and Quest is a trusted name in laboratory services known for high quality and innovation. We look forward to a collaboration with Quest that will maintain streamlined and efficient operations, quality and breadth of menu while enhancing access for our patients."
Mergian is also CEO and a distinguished chair at Jane and Henry Meyer.
In the same press release, Quest Diagnositcs chairman, CEO, and president Jim Davis said, “Top health systems like University Hospitals are transitioning their laboratory services to Quest in order to improve operating efficiency and ensure continued access to affordable care. Our specialization and scale empower us to optimize lab services for quality, innovation and affordability, enabling health systems to dedicate more resources to clinical patient care. We look forward to extending our presence in the many communities in Ohio that can benefit from our expertise."
This is the latest move by Quest Diagnositcs to expand its business. Earlier this month, the company announced the launch of 13 new blood tests designed to identify micronutrient deficiencies.2 The tests are consumer-initiated blood-draw tests and are available at questhealth.com.
In a press release, medical science liaison of consumer-initiated testing for questhealth.com Dr. Katrina Sutto, PharmD, said, “Studies have shown that key vitamins and nutrients such as iron, calcium, and magnesium are under-consumed or may be poorly absorbed in the body, which may have an adverse effect on people's health. What people may not realize is that their medications, allergies, chronic conditions and diets can affect how well their bodies can absorb these essential nutrients. In providing medically-informed testing solutions and detailed results through our various nutrient panels, we hope to empower people to seek the best pathway to help their overall wellbeing."
In the same press release, senior vice president and general manager of Quest Consumer Richard Adams said, “This expansion underscores our commitment to offering accessible, personalized, and consumer-driven health insights that can make a meaningful difference in our daily lives. Whether micronutrient deficiencies stem from dietary restrictions, medications, or chronic conditions, our tests provide consumers with valuable tools to take better control over their health."
Also in August, Quest released the results of a study in conducted that suggests that pregnant women in the United States are generally under-tested for sexually transmitted infections.3
In a press release, co-author of the study and medical director of women’s health at Quest Diagnostics Damian P. Alagia, MD, said, “Our study adds to a troubling body of evidence highlighting inconsistent quality in maternal and child healthcare in the U.S. Our analysis shows that improved adherence to existing recommendations, harmonization of guidelines across agencies, and even updated recommendations for STI testing will be critical to ensuring the mothers and babies in the United States receive medically appropriate testing and treatment."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.